“By fostering collaboration, UKDTN is strengthening the UK’s position in early-phase clinical trials and driving positive change across the dementia research landscape.”
UKDTN hosted a roundtable on improving diversity in dementia trials, generating actionable insights now being developed into a white paper, with further international engagement planned at CTAD 2025.
To support our mission of ensuring equitable access to clinical trials across all UK populations, UKDTN hosted an invite-only roundtable at AAIC in Toronto (July), focused on advancing diversity and inclusion in dementia trials. Bringing together international stakeholders from industry, academia, and charities, the session generated actionable recommendations for both immediate and long-term impact. A white paper is now in development to capture these insights. UKDTN’s next major international engagement will be at the UK Industry Liaison Forum during CTAD 2025, this December in San Diego.
By UKDTNAdmin